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Abstract: 
Pseudomonas aeruginosa is responsible for chronic infection in many bronchiectasis patients 
but it is not known whether it is associated with worse clinical outcomes independent of the 
underlying severity of disease. 
This study analyzed data from 2596 prospectively enrolled bronchiectasis patients in 10 different 
bronchiectasis clinical centres across Europe and Israel, with a 5-year follow-up period. 
Prevalence of P. aeruginosa chronic infection and its independent impact on exacerbations, 
hospitalizations, quality of life and mortality was assessed.  
The prevalence of P. aeruginosa chronic infection was 15.0% (n=389). P.aeruginosa was 
associated with a higher mortality in a univariate analysis (HR: 2.02; 95% CI 1.53–
2.66;p<0.0001) but an independent impact on mortality was not found in a multivariate 
analysis (HR: 0.98; 95% CI 0.70–1.36;p=0.89). P. aeruginosa was independently associated with 
increased mortality only in patients with frequent exacerbations (2 or more per year) (HR 2.03; 
95% CI 1.36–3.03;p=0.001). An independent association with worse quality of life of 7.46 
points (95% CI, 2.93-12.00; p=0.001) was found in a multivariable linear regression. P. 
aeruginosa was therefore found to be independently associated with exacerbation frequency, 
hospital admissions and worse quality of life. Mortality was increased in patients with P. 
aeruginosa particularly in the presence of frequent exacerbations.  
 
 
Take home message:  
Frequent exacerbations are the key determinants of long term outcome in patients with 
Pseudomonas aeruginosa chronic infection.  
 
 
 
 
 
 
 
 
 
Background: 
Bronchiectasis is a chronic and progressive respiratory disease characterized by permanent 
dilation of bronchi, impairment of mucus clearance, chronic cough and sputum production, and 
an increased frequency of respiratory infections.(1) Without effective mucociliary and innate 
antimicrobial defences, there is a higher risk of chronic bacterial infection of the airways which 
can lead to an increase in airway inflammation and structural damage.(2,3) 
Pseudomonas aeruginosa is one of the most important organisms causing chronic infection in 
bronchiectasis, because of its capacity to maintain virulence despite antibiotic therapies by 
forming biofilms and easily developing antimicrobial resistance.(4,5,6) P. aeruginosa in cystic 
fibrosis (CF) bronchiectasis is associated with a steeper decrease in lung function and increased 
morbidity and mortality.(7) Its presence in bronchiectasis seems to be linked with a more severe 
disease but whether there is a direct effect on disease progression or whether P. aeruginosa is 
just an indicator of existing clinical severity remains a topic of discussion.(8,9,10) 
In a recent meta-analysis, P. aeruginosa chronic infection was related to a threefold increase in 
mortality, as well a higher risk of hospital admissions and increased exacerbation frequency.(11) 
This study however, was not able to take into account the multiple confounders that are usually 
present in more severe bronchiectasis patients and that could play a role in mortality, such as 
FEV1 , co-morbidities or severe exacerbations. Moreover, there was some heterogeneity in 
terms of chronic infection definition and measured parameters across the different studies.(11) 
To definitively answer whether P. aeruginosa directly drives disease progression and mortality 
in bronchiectasis would require a longitudinal study able to identify the point at which P. 
aeruginosa infection first occurs and to compare morbidity before and after acquisition. As such 
studies are not currently available, an alternative method is to utilise multivariable modelling, 
which allows the estimation of the independent contribution of P. aeruginosa after removing 
the effects of confounding variables.  
The rate of P. aeruginosa chronic infection in bronchiectasis patients varies among the studies, 
between 9-31%, and its prevalence in a large, multicentre population from several different 
countries is yet to be assessed.(12-19) 
The aim of this study was to assess the burden of disease in P. aeruginosa chronic infection and 
its independent impact in terms of patient outcomes.  
 
Methods: 
This study analyzed data from prospectively enrolled bronchiectasis patients in 10 different 
bronchiectasis clinical centres across Europe (including Israel as an EU affiliated country) 
(Dundee, Edinburgh, Newcastle–United Kingdom; Haifa-Israel; Galway-Ireland; Leuven-Belgium; 
Athens-Greece; Monza-Italy; Barcelona-Spain; Vojvodina-Serbia) between 2007 and 2013. 
Consecutive patients aged ≥18 years with a diagnosis of bronchiectasis, made by a specialist 
physician, based on high-resolution computed tomographic scan and with a compatible clinical 
history (defined by the presence of respiratory symptoms attributable to bronchiectasis) were 
enrolled. Patients had to be free from antibiotic treatment for exacerbation for 4 weeks prior to 
enrolment and initial data collection. Patients with CF or traction bronchiectasis due to 
pulmonary fibrosis were excluded, as well as patients with active non-tuberculous mycobacterial 
disease. Local ethics committee or institutional review board, approved the data collection at 
each site. Diagnostic work-up and assessment was made following algorithms consistent with 
the 2010 British Thoracic Society (BTS) guidelines.(20) 
Identification of microorganisms and susceptibility testing were performed according to 
standard methods.(21) Chronic infection was defined by isolation of the same pathogen in two 
or more cultures, at least 3 months apart in a 12-month period.(20) 
Demographics, previous medical history, comorbidities, as well as radiological, laboratory and 
microbiological findings were obtained from a combination of direct patient history, medical 
records and laboratory information recorded at each site. Quality of life (QoL) was measured by 
the St. George’s Respiratory Questionnaire (SGRQ) and severity of disease was evaluated by the 
Bronchiectasis Severity Index (BSI).(22) There was a follow-up period of 5 years, in which 
exacerbations and hospitalizations were recorded, following BTS guidelines definitions, and 
mortality was assessed.   
 
Statistical analysis:  
Simple descriptive statistics of mean with standard deviation (SD) were used for continuous 
parametric data, median with 25-75% interquartile range (IQR) for continuous non-parametric 
data, and frequencies and percentages for categorical data. Subgroup comparisons were 
performed using the unpaired t-test, Mann-Witney U-Test or Chi-squared test, depending on 
data distribution. 
Kaplan–Meier curves were used to illustrate survival data. For multivariable mortality analysis, 
Cox proportional hazard regression analysis was performed to estimate hazard ratios (HR) and 
their 95% confidence intervals (CI). Variables included in the model were those determined by 
the investigators to be clinically significant in impacting on mortality.   
A multiple linear regression model was applied to determine the variables with an independent 
impact on QoL. To check the suitability of our model, we fitted a generalized linear model (GLM) 
with quasibinomial errors and a logit link. The signs and significance of every estimated 
parameter in this, matched its equivalent in the linear model. Estimates of the change in fitted 
values, from the GLM, on stepping one unit away from the centre of the dataset (the medians 
of all numerical values) in each direction all fell within the 95% CI around the betas in the linear 
model. However, while the model results are very similar, the terms within the generalized linear 
model are difficult to interpret. We have, therefore, described the results of the linear model.  
All analyses were performed using SPSS version 21 (SPSS, Chicago, IL, USA) for Windows platform 
and Graph Pad Prism Version 5 (Graph Pad Software, Inc. San Diego, CA, USA).  
 
 
 
 
 
 
Results: 
Patient characteristics:  
The study population was composed of 2596 patients. Individual inclusion per site was 608 in 
Edinburgh, 504 in Dundee, 116 in Newcastle, 280 in Galway, 190 in Leuven, 113 in Vojvodina, 88 
in Haifa, 159 in Athens, 198 in Barcelona and 340 in Monza. 
The patient characteristics are described in detail in table 1.  
The median age was 67 years (IQR – 57-74) and there was a female predominance (61.1%, 
n=1586). In terms of comorbidities, the highest reported conditions were ischaemic heart 
disease, 17.5% (n=453), Chronic Obstructive Pulmonary Disease (COPD), 16.6% (n=431), GERD, 
15.2% (n=394) and diabetes, 10.0% (n=260). The median BSI score was 6 (IQR – 4-10) with a 
homogenous distribution between the severity groups – Mild (0-4) (29.0%, n=753), Moderate 
(5-8) (35.7%, n=927), Severe (≥9) (35.3%, n=916). Patients had a median of 41.2 points in the 
SGRQ (IQR – 24.5 – 59.6). Most patients were classified as idiopathic (42%), with post-infective 
aetiology (17%), COPD (9%), asthma (6%), connective tissue diseases (6%) and allergic 
bronchopulmonary aspergillosis (5%) also being common in this cohort.  
At the time of enrolment, the median number of exacerbations in the previous year was 2 (IQR 
– 0-3), however, 37.2% (n=966) had 3 or more exacerbations over the same period, and 25.9% 
(n=672) had at least one hospitalization in the previous year.  
 
Pseudomonas aeruginosa chronic infection prevalence:   
Half of the study population had a chronic respiratory infection with at least one pathogen 
(50.1%, n=1300). The most common were Haemophilus influenzae (21.9%, 95% CI 20.4-23.6%, 
n=569) and P. aeruginosa (15.0%, 95% CI 13.7-16.4%, n=389). Rates of P. aeruginosa infection 
varied across different European centres, from the lowest in Serbia - 0.9% (95% CI, 0.2-4.8%), 
Belgium - 8.4% (5.3-13.2%), Italy - 12.1% (9.0-15.9%), UK - 12.5% (10.7-14.4%) and Ireland - 
13.9% (10.4-18.5%) to the highest rates in Spain - 21.2% (16.1-27.4%), Greece - 36.5% (29.4-
44.2%) and Israel - 44.3% (34.4-54.7%). Active NTM was excluded, but NTM isolation as baseline 
was reported in 46 subjects. 
 
Patient characteristics according to chronic infection status 
Patients with P.aeruginosa were slightly older (median (IQR), 70y (59-77y) vs 67y (57-74y) vs 66y 
(57-75y), p<0.001) and had a lower FEV1% (57.9% vs 69.2% vs 77.0%, p<0.001) than patients 
chronically infected with other pathogens or those not chronically infected respectively.(table 
3) They had more major cardiovascular comorbidities such as ischaemic heart disease and 
stroke. They had also more exacerbations on the previous year (median (IQR) – 3 (2-4) vs 2 (1-
3) vs 1 (0-2), p<0.001) and a higher percentage of patients with at least one hospital admission 
in the previous year (59.9% vs 31.9% vs 17.6%, p<0.000). The median BSI was higher in P. 
aeruginosa group (median (IQR) – 13 (10-17) vs 8 (5-13) vs 5 (3-8), p<0.001). Data are presented 
in Table 2.  
 
Mortality analysis:  
There were 281 deaths during the follow-up period, which accounted for 10.8% (95% CI 9.7-
12.1%) of the total study population. There were 73 deaths in 389 patients (18.8%) in the P. 
aeruginosa chronic infection group, 75 in 918 (8.2%) in the other pathogens chronic infection 
group and 133 in 1289 (10.3%) in patients with no chronic infection (p<0.0001 comparing all 3 
groups).  
A univariate analysis of the impact P. aeruginosa chronic infection had in terms of mortality, 
showed a higher mortality in the P. aeruginosa group versus all the other patients (HR: 2.02; 
95% CI, 1.53–2.66; p<0.0001).(Figure 1) 
A multivariate analysis was then performed with the variables that were determined to be 
clinically relevant affecting mortality.(Table 3) These results show that the presence of a P. 
aeruginosa chronic infection in isolation does not have an independent impact in terms of 
mortality (HR: 0.98; 95% CI 0.70 – 1.36; p=0.89). Other variables however, such as age (HR: 1.05; 
95% CI 1.04-1.07; p<0.001), exacerbation frequency (HR (per exacerbation): 1.06; 95% CI 1.01 – 
1.12; p=0.02) and hospitalized exacerbations (HR:1.60; 95% CI 1.17 – 2.19; p=0.003) had an 
independent contribution to a higher mortality.  
We hypothesized that mortality associated with P. aeruginosa chronic infection may be 
exacerbation dependent. A separate analysis in terms of mortality was made dividing the study 
population into 4 categories –  1) P. aeruginosa chronic infection with less than 2 exacerbations 
per year; 2) P. aeruginosa chronic infection with 2 or more exacerbations per year; 3) No P. 
aeruginosa and less than 2 exacerbations per year; 4) No P. aeruginosa and 2 or more 
exacerbations per year.  
Patients with P. aeruginosa and 2 or more exacerbations per year had the higher mortality rate 
(20.5%), followed by patients with frequent exacerbations without P. aeruginosa (12.5%). In 
those with less than 2 exacerbations per year, the mortality rate in the presence of P. aeruginosa 
chronic infection was 9.7% vs 6.7% in those without P. aeruginosa chronic infection. Of note, 
only 62 out of 389 patients with P. aeruginosa had less than 2 exacerbations per year.  
Survival curves of the 4 groups are presented on figure 2.  
A multivariate analysis was performed using the same variables (table 4). Having P. aeruginosa 
chronic infection with less than 2 exacerbations had no impact in terms of mortality (HR: 0.90; 
95% CI 0.39 – 2.12; p=0.81). Patients having 2 or more exacerbations per year had increased 
mortality (HR: 1.74; 95% CI 1.28–2.38; p<0.001) an effect that was magnified in the presence of 
P. aeruginosa (HR: 2.03; 95% CI 1.36–3.03; p=0.001). 
A sensitivity analysis accounting for centre as an independent variable in the analysis did not 
affect the conclusions (HR: 1.09, 95% CI 0.78-1.53;p=0.6) in the fully adjusted analysis. The same 
was observed in the analysis of subgroups by exacerbation history - P. aeruginosa plus a history 
of 2 exacerbations per year (HR: 2.22, 95% CI 1.44-3.43,p<0.0001), 2 or more exacerbations per 
year without P. aeruginosa (HR: 1.88, 95% CI 1.34-2.60,p<0.0001). P. aeruginosa without a 
history of frequent exacerbations was not associated with mortality (HR: 0.90, 95% CI 0.38-
2.12,p=0.8).  
 
Risk of exacerbations and hospital admissions: 
P. aeruginosa as well as H. influenzae chronic infection constituted predictors of future 
exacerbations (Incident rate ratio (95% CI)) - 1.14 (1.04-1.27) and 1.13 (1.03-1.24) respectively.  
Patients with P. aeruginosa chronic infection had a much higher probability of having a hospital 
admission on a univariate analysis (Odds ratio(OR): 4.96; 95% CI 3.96-6.22; p<0.001). This effect 
was also seen, although to a lesser degree, in a multivariable analysis (OR: 2.28; 95% CI 1.69-
3.08; p<0.001).   
 
Quality of life analysis:   
The median value of SGRQ in the P. aeruginosa group was 58.1 points (IQR – 54.0 – 62.2) and 
was higher than the median values for the other pathogens and the no chronic infection groups. 
A multivariable linear regression was performed showing an independent increase in the SGRQ 
of 7.46 points (95% CI 2.93-12.00; p=0.001), higher than the minimal clinically important 
difference (MCID) for SGRQ which is 4 points.(22) These results were confirmed on the 
generalized linear model with quasibinomial errors and a logit link.  
 
  
Discussion: 
This is the largest single study of bronchiectasis patients with the aim to assess the prevalence 
and burden of P. aeruginosa chronic infection.  
While multiple studies have reported an association between P. aeruginosa and more severe 
bronchiectasis, and some have shown an association with poorer clinical outcomes, these were 
predominantly single centre, with small samples sizes and could not provide any information as 
to whether P. aeruginosa was a cause of poor outcomes or simply a marker of more severe 
disease. Our study contributes to this debate by clearly demonstrating that after adjustment for 
multiple possible confounding variables, P. aeruginosa remains associated with increased 
exacerbations, increased hospital admission risk and worse quality of life. An association with 
mortality was only demonstrated in patients experiencing frequent exacerbations.  
The prevalence of P. aeruginosa chronic infection in this study population was 15.0%, which is 
in keeping with the ranges of prior publications (9-31%).(12-18) In a recent meta-analysis, Finch 
et al. identified a rate of P. aeruginosa colonization of 24.1%, but the various studies included 
had different definitions of chronic colonization with some regarding a single isolate as indicative 
of chronic infection.(11) Mortality in this study population, with a follow-up of 5 years, was 
10.8%, which is within the range of prior quoted studies over 4-5 years follow-up (Loebinger 9% 
at 4 years, Goeminne 20% at 5 years).(12, 24) 
Several studies have identified P. aeruginosa chronic infection as a risk factor for mortality in 
bronchiectasis patients.(11, 12, 22, 24, 25) A pooled OR for mortality was 2.95 (95% CI 1.98–
4.40; p<0.0001) in the Finch meta-analysis. In our cohort, on the univariate analysis, we had a 
HR of 2.02 (95% CI 1.53–2.66; p<0.0001). Because this group of patients has more risks factors 
than other groups, such as poorer lung function, increased age, certain comorbidities, it is 
important to clearly assess if P. aeruginosa really has an independent impact factor on mortality. 
In that matter, a multivariate analysis was performed. Herein independent predictors of 
mortality were age, low BMI, number of exacerbations, but in isolation, persistent infection with 
P. aeruginosa was not. 
To better understand why there was such a difference between univariate and multivariate 
analysis, the study population was divided into 4 groups (in terms of P. aeruginosa chronic 
infection and number of exacerbations) and a new multivariate analysis was performed. It 
became clear that having exacerbations plays a major role in mortality, independent of P. 
aeruginosa status.(26) This data strengthens the importance of reducing exacerbations in all 
bronchiectasis patients, particularly in the case of P. aeruginosa chronic infection, where a 
higher mortality risk is seen with frequent exacerbations.  
Even allowing for varying thresholds for admission across different healthcare systems, where 
home intravenous antibiotic may/may not be available, P. aeruginosa appears strongly 
correlated with exacerbation frequency and the risk of hospitalization. The risk of hospital 
admission is related to severity of disease, number of exacerbations, and the antibiotic 
susceptibility pattern of the pathogen responsible for the exacerbation, which in the case of P. 
aeruginosa is often limited to IV antibiotics.  
Quality of life was evaluated in this study using the SGRQ, which has been extensively validated 
in bronchiectasis patients.(27) P. aeruginosa chronic infection has been associated with a lower 
quality of life, and in the Finch et al. meta-analysis there was an 18.2 points decrement in the 
SGRQ.(11, 22, 27,28) The decrement justified by the presence of P. aeruginosa chronic infection 
was of 7.46 points (95% CI 2.93 – 12.00; p=0.001) which is considerably lower than the meta-
analysis result. However, since it was adjusted for multiple variables, it gives us a better 
understanding of the real impact of this chronic infection in QoL, and it is still clearly clinically 
significant and far above the MCID for SGRQ.  
If we accept now that there is robust evidence that P. aeruginosa drives worse outcomes in 
bronchiectasis, what are the clinical implications? First, a limited amount of observational data 
suggest that it may be possible to prevent P. aeruginosa chronic infection by giving eradication 
treatment with oral, intravenous and/or inhaled antibiotics in combination.(29) A conditional 
recommendation in favour of this approach was provided in the 2017 ERS bronchiectasis 
guidelines.(30) If P. aeruginosa infection cannot be prevented, then our data suggest that 
patients experiencing frequent exacerbations have the worst outcomes and so exacerbation 
prevention should be the key therapeutic focus. Long term macrolides have been shown to 
reduce exacerbation frequency in bronchiectasis, but these studies included few subjects with 
P. aeruginosa.(31) Inhaled antibiotics such as colistin, aminoglycosides and aztreonam have 
been tested in large populations of patients with P. aeruginosa with equivocal results.(30) Larger 
studies are awaited. The ERS bronchiectasis guidelines provided a conditional recommendation 
for the use of inhaled antibotics for patients with P. aeruginosa and 3 or more exacerbations per 
year, with macrolides to be added if inhaled antibiotics fail to control exacerbations.(30) Our 
results reinforce the importance of following these recommendations alongside optimising 
airway clearance, vaccination and the use of pulmonary rehabilitation in these patients.(30)  
The strengths of this study are the substantial number of patients included, the evaluation at 
different bronchiectasis clinical sites in different countries across Europe, and the considerable 
amount of patient data collected. A significant number of events, related to the large study 
population, enabled us to have a robust multivariate analysis with many variables, which helped 
to better understand the independent impact of P. aeruginosa chronic infection. Despite this, 
we acknowledge that the number of patients with P. aeruginosa not having frequent 
exacerbations was low. We cannot exclude the possibility that this group has an increased risk 
of death.  
The main limitation of this study is not having a description of the cause of death in all cohorts. 
It would have been useful to know the number of deaths associated with respiratory causes. 
Another important limitation is that P. aeruginosa diagnosis is based on sputum culture which 
is known to be insensitive, and the methods and frequency of sputum culture are not 
standardized.(32) This could potentially underestimate the frequency of P. aeruginosa chronic 
infection. Another limitation is the absence of an analysis of the impact that P. aeruginosa 
phenotype/strain type and resistance pattern could have in terms of patient’s outcomes.(32) 
This study gives us a more accurate view of the real P. aeruginosa chronic infection prevalence 
across Europe. It also enables us to better understand its burden of disease, with connection to 
poorer lung function, more exacerbations and hospitalizations and a worse quality of life. In 
terms of mortality, the relationship between P. aeruginosa and an increased risk of death, 
described previously in the literature, seems to be closely related with the fact that these 
patients have more exacerbations and more hospitalizations, rather than just the simple fact of 
being chronically infected by this pathogen. Our analysis cannot fully account for the “chicken 
or egg” question. It is not known whether patients with P. aeruginosa have more exacerbations 
and therefore have worse outcomes, or whether frequently exacerbating patients have a poor 
prognosis with frequent antibiotic courses leading to P. aeruginosa infection and poor 
outcomes. Our study can only demonstrate that the combination of these two parameters leads 
to increase mortality. This clarification could have major implications for healthcare policy, since 
either way it implies that adverse effects of P. aeruginosa may be mitigated by exacerbation 
prevention. Furthermore, it highlights the important impact of exacerbations in the non- 
Pseudomonas population validating this as a key therapeutic target. 
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Total, n (%) 2596 (100%) 
Demographics  
Age, yr, median, IQR 67 (57-74) 
≥ 65 years old, n (%) 1395 (53.7%) 
Male, n (%) 1010 (38.9%) 
BMI, kg/m2, median (IQR) 24.8 (21.8-28.1) 
Smokers and ex-smokers, n (%) 990 (38.1%) 
Comorbidities  
Ischaemic heart disease, n (%) 453 (17.5%) 
Stroke, n (%) 152 (5.9%) 
Diabetes, n (%) 260 (10.0%) 
Liver disease, n (%) 41 (1.6%) 
Chronic renal failure, n (%) 154 (5.9%) 
COPD, n (%) 431 (16.6%) 
Asthma, n (%) 226 (8.7%) 
Connective tissue disease, n (%) 210 (8.1%) 
Neurological disease, n (%) 68 (2.6%) 
Osteoporosis, n (%) 192 (7.4%) 
GERD, n (%) 394 (15.2%) 
Haematological malignancy, n (%) 33 (1.3%) 
Solid tumor, n (%) 164 (6.3%) 
Functional status  
FEV1 % predicted, median (IQR) 73.8% (54.0-92.1) 
FEV1 % predicted, < 50%, n (%) 502 (19.3%) 
Clinical status  
Exacerbations in the previous year, median 
(IQR) 
2 (0-3) 
 
3 or more exacerbations per year, n (%) 966 (37.2%) 
At least one hospitalization in the previous 
year, n (%) 
672 (25.9%) 
 
Disease severity  
BSI score, median (IQR) 6 (4-10) 
Mild BSI score (0–4), n (%) 753 (29.0%) 
Moderate BSI score (5–8), n (%) 927 (35.7%) 
Severe BSI score (>9), n (%) 916 (35.3%) 
Quality of life  
SGRQ, median (IQR) 
n=987 
41.2 (24.5-59.6) 
Table 1 - Patient Characteristics. BMI – Body mass index; COPD – Chronic obstructive lung 
disease; GERD – Gastroesophageal reflux disease; IQR – Interquartile Range; BSI – Bronchiectasis 
Severity Index; SGRQ - St. George’s Respiratory Questionnaire 
 
 
 
 
 
 P. aeruginosa 
chronic infection 
Other pathogen 
chronic infection 
No chronic 
infection 
p value 
Total, n (%) 389 (15.0%) 918 (35.4%) 1289 (49.7%)  
Demographics  
Age, yr, median, IQR 70 (59-77) 67 (57-74) 66 (57-75) p<0.001 
≥ 65 years old, n (%) 244 (62.7%) 685 (74.6%) 674 (52.3%) p<0.001 
Male, n (%) 167 (42.9%) 522 (41.7%) 468 (36.3%) p<0.001 
BMI, kg/m2, median (IQR) 24.9 (21.3-27.7) 
 
24.6 (21.4-27.7) 
 
25.2 (22.3-28.4) 
 
p<0.001 
Smokers and ex-smokers, n (%) 122 (31.4%) 457 (49.8%) 516 (40.0%) 
 
p<0.001 
Comorbidities  
Ischaemic heart disease, n (%) 64 (16.5%) 
 
251 (20.0%) 
 
190 (14.7%) 
 
p<0.001 
Stroke, n (%) 30 (7.7%) 79 (6.3%) 69 (5.4%) p=0.009 
Diabetes, n (%) 53 (13.6%) 115 (9.2%) 137 (10.6%) p=0.18 
Chronic Renal Failure, n(%) 23 (5.9%) 
 
61 (4.9%) 
 
88 (6.8%) 
 
p=0.82 
COPD, n (%) 78 (20.1%) 196 (15.7%) 229 (17.8%) p=0.10 
Haematological malignancy, n 
(%) 
9 (2.3%) 
 
22 (1.8%) 
 
11 (0.9%) 
 
p=0.009 
Solid tumor, n (%) 27 (6.9%) 88 (7.0%) 71 (5.5%) p=0.001 
Functional status  
FEV1 % predicted, median (IQR) 57.9 (42-77.7) 
 
69.2 (50-89.8) 
 
77.0 (59-95) 
 
p<0.001 
FEV1 % predicted, < 50%, n (%) 135 (34.7%) 
 
290 (31.6%) 
 
200 (15.5%) 
 
p<0.001 
Clinical status  
Exacerbations in the previous 
year, median (IQR) 
3 (2-4) 
 
2 (1-3) 
 
1 (0-2) 
 
p<0.001 
At least one hospitalization in 
the previous year, n (%) 
233 (59.9%) 
 
400 (31.9%) 
 
227 (17.6%) 
 
p<0.001 
Disease severity  
BSI score, median (IQR) 13 (10-17) 8 (5-13) 5 (3-8) p<0.001 
Mild BSI score (0–4), n (%) 0 (0%) 
 
209 (22.8%) 
 
543 (42.1%) 
 
p<0.001 
Moderate BSI score (5–8), n (%) 54 (13.9%) 
 
461 (50.2%) 
 
458 (35.5%) 
 
p<0.001 
Severe BSI score (>9), n (%) 335 (86.1%) 
 
581 (63.3%) 
 
288 (22.3%) 
 
p<0.001 
Quality of life  
SGRQ, median (IQR) 58.7 (42.0-79.3) 
n=125 
44.5 (26.8-62.6) 
n=517 
 
35.6 (21.0-52.3) 
n=345 
 
p<0.001 
 
Table 2 – Differences between patients with P. aeruginosa chronic infection, other pathogens 
chronic infection and no chronic infection 
 
 Variable Hazard ratio 
for death 
95% confidence 
interval 
p value 
P. aeruginosa chronic 
infection 
0.98 0.70 – 1.36 0.89 
Age (years) 1.05 1.04 - 1.07 <0.001 
Gender (male vs female) 1.29 0.99 – 1.67 0.06 
MRC dyspnea score 1.25 1.11 – 1.40 <0.001 
FEV1 groups    
<30% predicted 1.00 n/a reference 
30-49% predicted 0.66 0.43 – 0.99 0.05 
    50-79% predicted 0.44 0.29 – 0.68 <0.001 
80% or more predicted 0.45 0.28 – 0.73 0.001 
Hospitalized 
exacerbations 
1.60 1.17 – 2.19 0.003 
Radiology score (Reiff 
Score) 
1.02 0.99 – 1.06 0.17 
BMI <18.5 Kg/m2 1.70 1.14 – 2.54 0.01 
Smoking status 1.14 0.86 – 1.50 0.37 
Exacerbations in the 
previous year (HR per 
additional exacerbation) 
1.06 1.01 – 1.12 0.02 
H. influenzae chronic 
infection 
0.59 0.40 – 0.86 0.007 
S. aureus chronic 
infection 
1.69 1.10 – 2.60 0.02 
M. catarrhalis chronic 
infection 
0.72 0.39 – 1.33 0.30 
Enterobacteriaceae 
chronic infection 
0.71 0.44 – 1.15 0.16 
COPD 1.41 1.04 – 1.90 0.03 
Diabetes 1.27 0.92 – 1.75 0.14 
Chronic renal failure 1.46 1.03 – 2.06 0.03 
Ischemic heart disease 1.47 1.12 - 1.93 0.006 
Oral long term antibiotic 
suppressive therapy 
1.11 0.84 – 1.47 0.46 
Nebulized long term 
antibiotic suppressive 
therapy 
0.80 0.51 – 1.25 0.33 
Table 3 - Multivariate Cox regression analysis of factors associated with survival 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4 - Multivariate Cox regression analysis of factors associated with survival after 
categorization into 4 new groups 
Variable Hazard ratio 
for death 
95% confidence 
interval 
p value  
Groups    
No P. aeruginosa chronic 
infection with <2 
exacerbations per year 
1.00 reference n/a 
No P. aeruginosa chronic 
infection with ≥2 
exacerbations per year 
1.74 1.28 – 2.38 <0.001 
P. aeruginosa chronic 
infection with <2 
exacerbations per year 
0.90 0.39 – 2.12 0.81 
P. aeruginosa chronic 
infection with ≥2 
exacerbations per year 
2.03 1.36 – 3.03 0.001 
Age (years) 1.05 1.04 - 1.07 <0.001 
Gender (male vs female) 1.29 1.00 – 1.68 0.055 
Radiology score (Reiff 
Score) 
1.03 0.99 – 1.06 0.11 
BMI < 18.5 Kg/m2 1.68 1.13 – 2.50 0.011 
Smoking status 1.11 0.84 – 1.47 0.45 
MRC dyspnea score 1.24 1.16 – 1.45 <0.001 
FEV1 % predicted    
<30% predicted 1.00 Reference n/a 
30-49% predicted 0.66 0.44 – 1.00 0.048 
    50-79% predicted 0.41 0.27 – 0.62 <0.001 
80% or more predicted 0.43 0.27 – 0.68 <0.001 
H. influenzae chronic 
infection 
0.57 0.39 – 0.84 0.005 
S. aureus chronic infection 1.73 1.10 – 2.60 0.01 
M. catarrhalis chronic 
infection 
0.78 0.43 – 1.44 0.43 
Enterobacteriaceae chronic 
infection 
0.78 0.49 – 1.24 0.29 
COPD 1.33 0.98 – 1.81 0.07 
Diabetes 1.28 0.93 – 1.75 0.13 
Chronic renal failure 1.58 1.13 – 2.23 0.008 
Ischemic heart disease 1.46 1.11 - 1.92 0.007 
Oral long term antibiotic 
suppressive therapy 
1.14 0.86 – 1.49 0.36 
Nebulized long term 
antibiotic suppressive 
therapy 
0.79 0.51 – 1.25 0.32 
 
